

(MODIFIED) PATENT AND TRADE			MENT OF COMMERCE O TRADEMARK OFFICE	MERCE OFFICE Senal No. Applicant			50026/012003 09/905,592 Keiya Ozawa et al.		
	INFORMATION STATEMENT (Use several s	NT ·	Filing Date Group		July 13, 2001				
(37 C.F.R. § 1.	98(b))	·	<u> </u>	IDS Filed		February 19, 2004			
			U.S. PATENTS	:		· · · .			
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate)		
			· .			<u> </u>			
	FORE	IGN PATENT	OR PUBLISHED FOREIG	N PATENT A	PPLICATION	DN .			
Examiner's Initials	Document Number	Publication Date		Country or Class Patent Office		Subclass	Translation (Yes/No)		
				•			·		
1.2	OTHER DOCL	JMENTS (INCL	UDING AUTHOR, TITLE	, DATE, PLAC	E OF PUB	BLICATION)			
(Jaka)	<u> </u>		Nature 392(Supp.):25						
₩,~			bts on Future of Gene Th				 :		
On	Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" Journal of Hepatology 39:731-737 (2003).								
JD	Juengst, "What N	lext for Human	Gene Therapy' BMJ 326	:1410-1411 (2	003).				
2/2/09	Kekuta et al., Ini Cell Proliferation	nibition of B16.I and Activation	Melanoma Experimental of Antitumour Host Mech	Metastasis by anisms," Immo	Interferon- unology 10	2 through Dir 05:92-100 (20	ect Inhibition of 002).		
	Kmies "Gene The	Kmies "Gene Therapy" American Scientist 87:240-247 (1999).							
	Marcinkowska and Wiedlocha "Steroid Signal Transduction Activated at the Cell Membrane: from Plants to Animals," Acta Biochimica Polonica 49(3):735-745 (2002).								
Manuyama et al "Proliferation and England Differentiation through the Cytoplasmic Dor Receptor," The Journal of Biological Chemistry, 269(8):5976-5980 (1994).							of the Erythropoiet		
	Farrell et al., Evidence for Sta	t-10 Inhibits M	acrophage Activation and and Independent Pathwe	Proliferation	by Distinc	t Signaling M 17(4):1006-	lechanisms: 1018 (1998).		
	Verma and Somi	Verma and Somie, "Gene Therapy-Promises, Problems and Prospects," Nature 389:239-242 (1997).							
	Wang et al., "Yea is Vivo," The Jou	Wang et al., "Yeast Two-Hybrid System Demonstrates that Estrogen Receptor Dimerization Is Ligand-Dependent Vivo," The Journal of Biological Chemistry, 270(40):23322-23329 (1995).							
	Winamel et al., "/ Neuroendoonne	Autocrine Grow Tumour Cells,	th Inhibition by Transform Gut 52:1308-1316 (200	ing Growth F 3).	actor β-1 (TGFB-1) in l	luman		
				<u> </u>					



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE					Attorney Docket No.		50026/012003	
					Serial No.		09/905,592	
	Applicant		Keiya Ozawa et al.					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					Filing Date Group		July 13, 2001 1636	
:		•	U.S. PATENTS					
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate)	
		<u> </u>		,			l <u>:</u>	
	FORE	IGN PATENT C	R PUBLISHED FOREIGI	N PATENT A	PPLICATIO	ON .		
Examiner's	Examiner's Document Publication Count			OF .	Class	Subclass	Translation	
Initials	Number	Date	Patent Off	ent Office			(Yes/No)	
	WQ 02/10151	- May 27, 199	3 WIPO				j	
white	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE,	DATE, PLAC			nverter for the LII	
Duplin	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE,	DATE, PLAC			nverter for the LII	
over over	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE, ransducer, gp130: An Or 134-1437 (1992).	DATE, PLAC			niverter for the LII	
) unlive	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE,	DATE, PLAC			nverter for the LII	
) unlive	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE, ransducer, gp130: An Or 134-1437 (1992).	DATE, PLAC			nverter for the LII	
Suplier	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE, ransducer, gp130: An Or 134-1437 (1992).	DATE, PLAC			nverter for the LII	
) unlive	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE, ransducer, gp130: An Or 134-1437 (1992).	DATE, PLAC			nverter for the Lil	
) unlive	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE, ransducer, gp130: An Or 134-1437 (1992).	DATE, PLAC			nverter for the LII	
) unlive	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE, ransducer, gp130: An Or 134-1437 (1992).	DATE, PLAC			nverter for the Lil	
Suplier	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE, ransducer, gp130: An Or 134-1437 (1992).	DATE, PLAC			niverter for the LII	
Duplin	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE, ransducer, gp130: An Or 134-1437 (1992).	DATE, PLAC			nverter for the LII	
Suplier	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE, ransducer, gp130: An Or 134-1437 (1992).	DATE, PLAC			nverter for the Lli	
Duplin	OTHER DOCL	JMENTS (INCLI	JDING AUTHOR, TITLE, ransducer, gp.130: An Or 134-1437 (1992).	DATE, PLAC	Beeptor an		nverter for the Lli	

					Silection	
		•	ocket No.	50026/01		
•				09/905,592		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)					Keiya Ozawa et al.	
					July 13, 2001	
,					1636	
(37 C.F.R. § 1.98(b))					May 26, 2004	
Patent Number Issue Date Paten		e	Class	Subclass	Filing Date (If Appropriate)	
EIGN PATENT OR	PUBLISHED FOREIGN	PATENT AF	PLICATIO	N		
Publication Date			Class	Subclass	Translation (Yes/No)	
				٠		
UMENTS (INCLUD	ING AUTHOR, TITLE, D	ATE, PLAC	E OF PUBI	LICATION)		
					onstitutive	
Bazan, "Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily," Proc. Natl. Acad. Sci. USA 87:6934-6938 (1990).						
ition of Cell Surface	e Receptors in Signal Tr	ansduction,"	Cell 80:21	3-223 (1995)).	
eceptor Signalling,"	Nature 377:591-594 (1	995).				
				r gp130 ls Co	onserved in the	
2002/0004582 A1,	published January 10,	2002.	-			
2003/0166161 A1,	published September 0	4, 2003.				
				rophilic Nucl	ear Lobulation by	
<u> </u>						
				,		
	DATE CO	NSIDERED	4/2	555		
ered. Draw line the	ough citation if not in co	nformance a	nd not con	sidered. Ind	ude copy of this	
	PATENT AND TO PATENT AND TO PUBLICANT Sheets if necessary sheets i	U.S. PATENTS Issue Date Patente EIGN PATENT OR PUBLISHED FOREIGN Publication Country or Patent Offic UMENTS (INCLUDING AUTHOR, TITLE, Date Patent Offic "Point Mutations within a Dimer Interface Heard Tumorigenicity," The EMBO Journal 1- al Design and Molecular Evolution of a Cytological Cytoplasmic Receptors in Signal Traceceptor Signalling," Nature 377:591-594 (1970) "Critical Cytoplasmic Region of the Interleur or Family," Proc. Natl. Acad. Sci. USA 88:11- 2002/0004582 A1, published January 10, 22003/0166161 A1, published September 01- Cocleration of Granulocyte Colony-Stimulating of Lyn Tyrosine Kinase," Eur. J. Biochem. 2 tion of Vertebrate Steroid Receptors from a Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial Genome Expansions," Proc. Natl. Acad. Serial Genome Expansions, "Proc. Natl. Acad. Serial G	Serial No. Applicant Sheets if necessary) ION DISCLOSURE IT BY APPLICANT Sheets if necessary) ION DATE CONSIDERED ION DISCLOSURE IT BY APPLICANT Sheets if necessary) ION DATE CONSIDERED ION DISCLOSURE IT BY APPLICANT Sheets if necessary) ION DATE CONSIDERED ION DISCLOSURE IT BY APPLICANT Sheets if necessary) ION DATE CONSIDERED ION DISCLOSURE IT BY APPLICANT Sheets if necessary IDN DATE CONSIDERED ION DISCLOSURE IT BY APPLICANT SHEETS IN DATE OF CONSIDERED ION DISCLOSURE IN DATE CONSIDERED ION DATE CONSIDERED	PATENT AND TRADEMARK OFFICE ION DISCLOSURE IT BY APPLICANT sheets if necessary) IDS Filted U.S. PATENTS Issue Date Patentee Class U.S. PATENT APPLICATION Publication Date Publication Date Point Mutations within a Dimer Interface Homology Domain of c-hand Tumorigenicity," The EMBO Journal 14(22):5569-5578 (1995) al Design and Molecular Evolution of a Cytokine Receptor Superfa 38 (1990). ation of Cell Surface Receptors in Signal Transduction," Cell 80:21 eceptor Signalling," Nature 377:591-594 (1995). "Critical Cytoplasmic Region of the Interleukin 6 Signal Transduce or Family," Proc. Natl. Acad. Sci. USA 88:11349-11353 (1991). 2002/0004582 A1, published January 10, 2002. 2003/0166161 A1, published September 04, 2003. coeleration of Granulocyte Colony-Stimulating Factor-Induced Neutof Lyn Tyrosine Kinase," Eur. J. Biochem. 269:381-389 (2002). DATE CONSIDERED DATE CONSIDERED	PATENT AND TRADEMARK OFFICE PATENT AND TRADEMARK OFFICE Serial No. Applicant Sheets if necessary) U.S. PATENTS Issue Date Patentee Patent OF Publication Date Publication Date Patent Office Patent Office U.S. PATENT APPLICATION Publication Date Patent Office Class Subclass UMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Point Mutations within a Dimer Interface Homology Domain of c-Mpl Induce Co and Tumorigenicity, "The EMBO Journal 14(22):5569-5578 (1995). All Design and Molecular Evolution of a Cytokine Receptor Superfamily," Proc. 1938 (1990). Atton of Cell Surface Receptors in Signal Transduction," Cell 80:213-223 (1995) eceptor Signalling," Nature 377:591-594 (1995). Critical Cytoplasmic Region of the Interleukin 6 Signal Transducer gp130 is Cor Family," Proc. Natl. Acad. Sci. USA 88:11349-11353 (1991). 2002/0004582 A1, published January 10, 2002. 2003/0166161 A1, published January 10, 2002. 2003/0166161 A1, published September 04, 2003. Coleration of Granulocyte Colony-Stimulating Factor-Induced Neutrophilic Nucl of Lyn Tyrosine Kinase," Eur. J. Biochem. 269:3381-3389 (2002). DATE CONSIDERED DATE C	



Sheet 1 of 1

				,,,,,		- 0/16	etiori	
	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.		50026/012003			
(MODIFIED)	MODIFIED) FAILINI AND THOSE MARK OF THE				Serial No.		09/905,592	
	INFORMATION DISCLOSURE					Keiya Ozawa et al. July 13, 2001 1655		
•	Filing Date Group							
(37 C.F.R. §1.98	IDS Filed		September 19, 2002					
			U.S. PATENTS				•	
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate	
<u></u>	FORE	IGN PATENT C	OR PUBLISHED FOREIGN	N PATENT A	PPLICATIO	DN		
Examiner's Initials			Class	Subclass	Translation (Yes/No)			
M	Chan et al., "A	Murine Cytoki	UDING AUTHOR, TITLE, Ine Fusion Toxin Specifing Factor (GM-CSF) FF-Dependent Tumor Ce	ically Targe	ting the N	Murine Gran	Bone Marrow	
	Ito et al. "G-CS	SFR-Fstrogen	R Fusion cDNA as a N	ovel Select	ive Ampli	fier Gene fo	r Controllable	
	Jackson et al., "Hormone-Conditional Transformation by Fusion Proteins of c-Abl and its Transforming Variants," <i>EMBO J</i> 12:2809-2819 (1993).							
	Nagata and Fukunaga, "Granulocyte Colony-Stimulating Factor and its Receptor," <i>Prog. Growth Factor Res.</i> , 3:131-141 (1991).							
	Ozawa et al., "Development of a Novel Selective Amplifier Gene for In Vivo Selective Expansion of Transduced Hematopoietic Stem Cells," (Abstract 161) Experimental Hematology 24:1053 (1996).							
	Transduced He							
M_{\perp}	Transduced He	ark. "Hemator	Stem Cells," (Abstract 1 poletic Effects of a Gran Protein," Cancer 67 (Sup	nulocyte-Ma	crophage	Colony-Sti		
EXAMINER	Transduced He	ark. "Hemator	poletic Effects of a Gran Protein," Cancer 67(Sup	nulocyte-Ma	105-2707	Colony-Sti		

50026.012003 Supplemental Form PTO-1449.doc

OIPE TO 2 3 ZONA W

RECEIVED

FEB 2 7 2004

Sheet 1 of 1

SUBSTITUTE	FORM PTO-1449		S. DEPARTMENT OF COMMERCE		Attorney Docket No.		50026/012003		
(MODIFIED)		PATENT AN	D TRADEMARK OFF	ICE	Serial No.		09/905,592		
 					Applicant		Keiya Ozawa et al.		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date	•	July 13, 2	001	
(Use several sheets if necessary)					Group		1636	1636	
(37 C.F.R. § 1.98(b))				IDS Filed		February	February 19, 2004		
			U.S. PATENT	rs	<u> </u>		<u> </u>		
Examiner's Initials			tee		Class	Subclass	Filing Date (If Appropriate)		
			Y		,				
	FORE	IGN PATENT (IOR PUBLISHED FOR	REIGN	PATENT AF	PPLICATIO	N	1	
Examiner's Initials	Document Number	Publication Date		intry o		Class	Subclass	Translation (Yes/No)	
	OTHER DOCL	IMENTS (INCL	UDING AUTHOR, TI	TLE, C	DATE, PLAC	E OF PUBL	ICATION)	<u> </u>	
M	Anderson, "Huma	n Gene Therap	oy" Nature 392(Supp.)	:25-3	0 (1998).				
	Cheok, "Cancer Fears Cast Doubts on Future of Gene Therapy" Nature 421:678 (2003).								
	Cui et al., "Inhibitory Effect of a Soluble Transforming Growth Factor β Type II Receptor on the Activation of Rat Hepatic Stellate Cells in Primary Culture" <i>Journal of Hepatology</i> 39:731-737 (2003).								
	Juengst, "What N	ext for Human	Gene Therapy" BMJ	326:14	110-1411 (20	03).			
			Melanoma Experiment of Antitumour Host Me						
	Kmiec "Gene The	rapy" American	Scientist 87:240-247	(199	9).				
			Steroid Signal Transdu ica 49(3):735-745 (20		Activated at	the Cell Me	embrane: fro	m Plants to	
	Maruyama et al., "Proliferation and Erythroid Differentiation through the Cytoplasmic Domain of the Erythropoietin Receptor," The Journal of Biological Chemistry, 269(8):5976-5980 (1994).								
	O'Farrell et al., "IL-10 Inhibits Macrophage Activation and Proliferation by Distinct Signaling Mechanisms: Evidence for Stat3-Dependent and -Independent Pathways," <i>The EMBO Journal</i> 17(4):1006-1018 (1998).								
	Verma and Somia	, "Gene Thera	py-Promises, Problem	ns and	Prospects,"	Nature 389	9:239-242 (1	997).	
			System Demonstrates at Chemistry, 270(40)				erization Is L	igand-Dependent	
M			n Inhibition by Transfo Gut 52:1308-1316 (20		Growth Fac	tor β-1 (TG	Fβ-1) in Hur	man ·	
EXAMINER	Kh		DA	TE CC	NSIDERED	4/2	5/05		
EXAMINER: In	nitial citation conside	red. Draw line	through citation if no	t in co	nformance a	nd not con	sidered. Inc	lude copy of this	

form with the next communication to applicant.

APR 2 0 2004 CO

Sheet 1 of 1

						,	eet i oi t	
SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE					Attorney Docket No.		50026/012003	
					Serial No.		09/905,592	
	AN 01001 ACU	Applicant	Applicant		Keiya Ozawa et al.			
s ⁻	ON DISCLOSU IT BY APPLICA	Filing Date		July 13, 2001				
(Us	sheets if necess	Group		1636				
(37 C.F.R. §1.98(b))	(37 C.F.R. §1.98(b))						April 16, 2004	
			U.S. PATENTS					
Examiner's Patent Initials	Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate)	
	FORE	IGN PATENT C	R PUBLISHED FOREIG	N PATENT A	PPLICATIO	N		
	ment	Publication			Class	Subclass	Translation	
	mber 3/10151	Date May 27, 199	Patent Off WIPO	ice			(Yes/No)	
отн	ER DOCL		JDING AUTHOR, TITLE,	DATE, PLAC	E OF PUBI	ICATION)		
M Gearing Recept	g et al., "Ti or," Scient	he IL-6 Signal T ce 255(5050):14	ransducer, gp130: An Or 34-1437 (1992).	costatin M R	eceptor and	Affinity Co	nverter for the LIF	
								
								
				· · · · · · · · · · · · · · · · · · ·			· · · · · · · · · · · · · · · · · · ·	
								
		-						
	>//							
EXAMINER	_//_		DATE C	ONSIDERED	4/2	5/05		
EXAMINER: Initial citati form with the next comm	on conside	ered. Draw line to applicant.	through citation if not in c	onformance	and not con	sidered. Inc	clude copy of this	

Sheet 1 of 1 50026/012003 Attorney Docket No. U.S. DEPARTMENT OF COMMERCE **ESTITUTE FORM PTO-1449** (MODIFIED) PATENT AND TRADEMARK OFFICE Serial No. 09/905,592 Applicant Ozawa et al. INFORMATION DISCLOSURE Filing Date July 13, 2001 STATEMENT BY APPLICANT (Use several sheets if necessary) 1636 Group **IDS Filed** (37 C.F.R. § 1.98(b)) February 24, 2005 **U.S. PATENTS** Issue Date Subclass Filing Date Patentee Class Patent Number Examiner's (If Appropriate) Initials FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION **Subclass** Translation Publication Class Examiner's Country or Document · (Yes/No) Initials Number Date Patent Office JP 8-504320A 14 May 1996 Japan Yes OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) DATE CONSIDERED 4/25/05 EXAMINER

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

50026/012003 Attorney Docket No. U.S. DEPARTMENT OF COMMERCE SUBSTITUTE FORM PATENT AND TRADEMARK OFFICE (MODIFIED) 09/905,592 Serial No. Ozawa et al. **Applicant** INFORMATION DISCLOSURE Filing Date July 13, 2001 STATEMENT BY APPLICANT (Use several sheets if necessary) 1636 Group IDS Filed October 20, 2004 (37 C.F.R. § 1.98(b)) U.S. PATENTS Filing Date Patentee Class Subclass Patent Number **Issue Date** Examiner's (If Appropriate) Initials FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION Class Subclass Translation Country or Document **Publication** Examiner's (Yes/No) Patent Office Date Number Initials OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION) Baumann et al., "Signaling by the Cytoplasmic Domain of Hematopoietin Receptors Involves Two Distinguishable Mechanisms in Hepatic Cells," J Biol Chem. 269(23):16297-16304 (1994). Skoda et al., "Murine *c-mpl*: a Member of the Hematopoietic Growth Factor Receptor Superfamily that Transduces a Proliferative Signal," *EMBO J.* 12(7):2645-2653 (1993). Vigon et al., "Characterization of the Munne Mpl Proto-Oncogene, a Member of the Hematopoietic Cytokine Receptor Family: Molecular Cloning, Chromosomal Location and Evidence for a Function in Cell Growth," Oncogene 8(10):2607-2615 (1993). DATE CONSIDERED S EXAMINER EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this

form with the next communication to applicant.